There's more to flow-mediated dilation than nitric oxide

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 7, 2012, Pages 589-600

  Stoner, Lee ^a   Erickson, Melissa Lynn ^b   Young, Joanna Mary ^c   Fryer, Simon ^d   Sabatier, Manning Joseph ^e   Faulkner, James ^a   Lambrick, Danielle Marie ^f   McCully, Kevin Kane ^b  

^a MASSEY UNIVERSITY   (New Zealand)

^b UNIVERSITY OF GEORGIA   (United States)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d UNIVERSITY OF CANTERBURY   (New Zealand)

^e EMORY UNIVERSITY   (United States)

^f MASSEY UNIVERSITY   (New Zealand)

Author keywords

Cardiovascular disease; Endothelial derived hyperpolarizing factor; Endothelium; FMD; Prostacyclin; Shear stress

Indexed keywords

CALCIUM ION; CALMODULIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FLUCONAZOLE; N(G) METHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROSTACYCLIN;

ARTERY DIAMETER; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; FLOW MEDIATED DILATION; HUMAN; NONHUMAN; PROGNOSIS; REVIEW; SHEAR STRESS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

BIOLOGICAL MARKERS; DILATATION, PATHOLOGIC; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; VASODILATION;

EID: 84864502123     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.11973     Document Type: Review

References (147)

1. Association AH: Heart Disease and Stroke Statistics - 2006. Update. 2006;
2. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature, 1993; 362: 801-809
3. Quyyumi AA: Prognostic value of endothelial function. Am J Cardiol, 2003; 91: 19H-24H
4. Cohn J: Vascular wall function as a risk marker for cardiovascular disease. Journal of Hypertension, 1999; 17: S41-S44
5. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992; 340: 1111-1115
6. Inaba Y, Chen JA, Bergmann SR: Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging, 2010; 26: 631-640
7. Frick M, Suessenbacher A, Alber H F, Dichtl W, Ulmer H, Pachinger O, Weidinger F: Prognostic value of bra-chial artery endothelial function and wall thickness. J Am Coll Cardiol, 2005; 46: 1006-1010
8. Schroeder S, Enderle MD, Ossen R, Meisner C, Baum-bach A, Pfohl M, Herdeg C, Oberhoff M, Haering HU, Karsch KR: Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiog-raphy, and myocardial perfusion imaging. Am Heart J, 1999; 138: 731-739
9. Koller A, Sun D, Kaley G: Role of shear stress and endo-thelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res, 1993; 72: 1276-1284
10. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G: Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension, 2011; 57: 363-369
11. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation, 1995; 91: 1314-1319
12. Kooijman M, Thijssen DH, de Groot PC, Bleeker MW, van Kuppevelt HJ, Green DJ, Rongen GA, Smits P, Hopman MT: Flow-mediated dilatation in the superficial femoral artery is nitric oxide mediated in humans. J Physiol, 2008; 586: 1137-1145
13. Gao Y: The multiple actions of NO. Pfl.gers Arch, 2010; 459: 829-839
14. Michel T, Vanhoutte PM: Cellular signaling and NO production. Pfl.gers Arch, 2010; 459: 807-816
15. Moncada S, Higgs EA: Nitric oxide and the vascular endothelium. Handb Exp Pharmacol, 2006; 213-254
16. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ: Nitric oxide and atherosclerosis: An update. Nitric Oxide, 2006; 15: 265-279
17. Bryan RM Jr, You J, Golding EM, Marrelli SP: Endo-thelium-derived hyperpolarizing factor: a cousin to nitric oxide and prostacyclin. Anesthesiology, 2005; 102: 1261-1277
18. Taylor SG, Weston AH: Endothelium-derived hyperpolar-izing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci, 1988; 9: 272-274
19. McLean PG, Aston D, Sarkar D, Ahluwalia A: Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reper-fusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res, 2002; 90: 465-472
20. Golding EM, You J, Robertson CS, Bryan RM: Potentiated endothelium-derived hyperpolarizing factor-mediated dilations in cerebral arteries following mild head injury. J Neurotrauma, 2001; 18: 691-697
21. Malmsjo M, Bergdahl A, Zhao XH, Sun XY, Hedner T, Edvinsson L, Erlinge D: Enhanced acetylcholine and P2Y-receptor stimulated vascular EDHF-dilatation in congestive heart failure. Cardiovasc Res, 1999; 43: 200-209
22. Brandes R P, Behra A, Lebherz C, Boger RH, Bode-Boger SM, Phivthong-Ngam L, Mugge A: N(G)-nitro-L-argi-nine- and indomethacin-resistant endothelium-depen-dent relaxation in the rabbit renal artery: effect of hyper-cholesterolemia. Atherosclerosis, 1997; 135: 49-55
23. Thollon C, Fournet-Bourguignon M P, Saboureau D, Lesage L, Reure H, Vanhoutte PM, Vilaine JP: Consequences of reduced production of NO on vascular reactivity of porcine coronary arteries after angioplasty: importance of EDHF. Br J Pharmacol, 2002; 136: 1153-1161
24. Miura H, Wachtel RE, Liu Y, Loberiza FR Jr, Saito T, Miura M, Gutterman DD: Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-acti-vated K(+) channels. Circulation, 2001; 103: 1992-1998
25. FitzGerald GA, Smith B, Pedersen AK, Brash AR: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med, 1984; 310: 1065-1068
26. Mayahi L, Mason L, Bleasdale-Barr K, Donald A, Tren-der-Gerhard I, Sweeney MG, Davis MB, Wood N, Mathias CJ, Watson L, Pellerin D, Heales S, Deanfield JE, Bhatia K, Murray-Rust J, Hingorani AD: Endothe-lial, sympathetic, and cardiac function in inherited (6R)-L-erythro-5,6,7,8-tetrahydro-L-biopterin deficiency. Circ Cardiovasc Genet, 2010; 3: 513-522
27. Hornig B, Maier V, Drexler H: Physical training improves endothelial function in patients with chronic heart failure. Circulation, 1996; 93: 210-214
28. Ghiadoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Giannarelli C, Taddei S, Salvetti A: Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hyper-tens, 2007; 25: 361-366
29. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR: Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol, 2009; 297: H425-H432
30. Westby CM, Weil BR, Greiner JJ, Stauffer BL, DeSouza CA: Endothelin-1 vasoconstriction and the age-related decline in endothelium-dependent vasodilatation in men. Clin Sci (Lond), 2011; 120: 485-491
31. Berger R, Stanek B, Hulsmann M, Frey B, Heher S, Pacher R, Neunteufl T: Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure. Circulation, 2001; 103: 981-986
32. Casey D P, Nichols WW, Conti CR, Braith RW: Relationship between endogenous concentrations of vasoac-tive substances and measures of peripheral vasodilator function in patients with coronary artery disease. Clin Exp Pharmacol Physiol, 2010; 37: 24-28
33. Cheetham C, O'Driscoll G, Stanton K, Taylor R, Green D: Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci (Lond), 2001; 100: 13-17
34. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, Ellahham S, Quyyumi AA: Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation, 2000; 101: 2349-2354
35. Weil BR, Westby CM, Van Guilder G P, Greiner JJ, Stauffer BL, DeSouza CA: Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol, 2011; 301: H689-H695
36. Bestle MH, Norsk P, Bie P: Fluid volume and osmoregu-lation in humans after a week of head-down bed rest. Am J Physiol Regul Integr Comp Physiol, 2001; 281: R310-R317
37. Maeda S, Miyauchi T, Kakiyama T, Sugawara J, Iemitsu M, Irukayama-Tomobe Y, Murakami H, Kumagai Y, Kuno S, Matsuda M: Effects of exercise training of 8 weeks and detraining on plasma levels of endothelium-derived factors, endothelin-1 and nitric oxide, in healthy young humans. Life Sci, 2001; 69: 1005-1016
38. Wang TD, Wang YH, Huang TS, Su TC, Pan SL, Chen SY: Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. J Formos Med Assoc, 2007; 106: 919-928
39. Spieker LE, Luscher TF, Noll G: ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans. J Cardiovasc Pharmacol, 2003; 42: 315-318
40. Varin R, Mulder P, Tamion F, Richard V, Henry J P, Lal-lemand F, Lerebours G, Thuillez C: Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation, 2000; 102: 351-356
41. Peretz A, Leotta D F, Sullivan JH, Trenga CA, Sands FN, Aulet MR, Paun M, Gill EA, Kaufman JD: Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Car-diovasc Disord, 2007; 7: 11
42. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol, 2002; 39: 257-265
43. Harris RA, Nishiyama SK, Wray DW, Richardson RS: Ultrasound assessment of flow-mediated dilation. Hypertension, 2010; 55: 1075-1085
44. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ: Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol, 2011; 300: H2-H12
45. Stoner L, Sabatier M: Assessment of endothelial function using ultrasound. Journal of Atherosclerosis and Thrombosis, 2012; 19: 407-421
46. Stoner L, Sabatier M, VanhHiel L, Groves D, Ripley D, Palardy G, McCully K: Upper vs lower extremity arterial function after spinal cord injury. J Spinal Cord Med, 2006; 29: 138-146
47. Stoner L, Sabatier MJ, Mahoney ET, Dudley GA, McCully KK: Electrical stimulation-evoked resistance exercise therapy improves arterial health after chronic spinal cord injury. Spinal Cord, 2007; 45: 49-56
48. Parker BA, Ridout SJ, Proctor DN: Age and flow-mediated dilation: a comparison of dilatory responsiveness in the brachial and popliteal arteries. Am J Physiol Heart Circ Physiol, 2006; 291: H3043-3049
49. Tinken TM, Thijssen DH, Black MA, Cable NT, Green DJ: Time course of change in vasodilator function and capacity in response to exercise training in humans. J Physiol, 2008; 586: 5003-5012
50. De Groot PC, Poelkens F, Kooijman M, Hopman MT: Preserved Flow Mediated Dilation in the inactive legs of spinal cord-injured individuals. Am J Physiol Heart Circ Physiol, 2004; 287: H374-H380
51. Wray DW, Uberoi A, Lawrenson L, Richardson RS: Evidence of preserved endothelial function and vascular plasticity with age. Am J Physiol Heart Circ Physiol, 2006; 290: H1271-H1277
52. Thijssen DH, Dawson EA, Black MA, Hopman MT, Cable NT, Green DJ: Heterogeneity in conduit artery function in humans: impact of arterial size. Am J Physiol Heart Circ Physiol, 2008; 295: H1927-1934
53. Celermajer DS, Sorensen KE, Bull C, Robinson J, Dean-field JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol, 1994; 24: 1468-1474
54. Mitchell G F, Parise H, Vita JA, Larson MG, Warner E, Keaney JF Jr, Keyes MJ, Levy D, Vasan RS, Benjamin EJ: Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension, 2004; 44: 134-139
55. Tinken TM, Thijssen DH, Hopkins N, Black MA, Dawson EA, Minson CT, Newcomer SC, Laughlin MH, Cable NT, Green DJ: Impact of shear rate modulation on vascular function in humans. Hypertension, 2009; 54: 278-285
56. Chironi G, Craiem D, Miranda-Lacet J, Levenson J, Simon A: Impact of shear stimulus, risk factor burden and early atherosclerosis on the time-course of brachial artery flow-mediated vasodilation. J Hypertens, 2008; 26: 508-515
57. Reneman RS, Arts T, Hoeks AP: Wall shear stress--an important determinant of endothelial cell function and structure--in the arterial system in vivo. Discrepancies with theory. J Vasc Res, 2006; 43: 251-269
58. Silber HA, Ouyang P, Bluemke DA, Gupta SN, Foo TK, Lima JA: Why is flow-mediated dilation dependent on arterial size? Assessment of the shear stimulus using phase-contrast magnetic resonance imaging. Am J Physiol Heart Circ Physiol, 2005; 288: H822-H828
59. Pyke KE, Tschakovsky ME: The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol, 2005; 568: 357-369
60. Stoner L, Sabatier M, Edge K, McCully K: The relationship between blood velocity and conduit artery diameter, and the effects of smoking on vascular responsiveness. J Appl Physiol, 2004; 96: 2139-2145
61. Stoner L, Sabatier MJ, Black CD, McCully KK: Occasional cigarette smoking chronically affects arterial function. Ultrasound Med Biol, 2008; 34: 1885-1892
62. Barakat AI: Responsiveness of vascular endothelium to shear stress: potential role of ion channels and cellular cytoskeleton (review). Int J Mol Med, 1999; 4: 323-332
63. Davies PF: Flow-mediated endothelial mechanotrans-duction. Physiol Rev, 1995; 75: 519-560
64. Fisher AB, Chien S, Barakat AI, Nerem RM: Endothe-lial cellular response to altered shear stress. 2001; 281: L529-L533
65. Fleming I, Busse R: Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol, 2003; 284: R1-R12
66. Labrador V, Chen KD, Li YS, Muller S, Stoltz J F, Chien S: Interactions of mechanotransduction pathways. Biorheology, 2003; 40: 47-52
67. Shyy JYJ, Chien S: Role of Integrins in Endothelial Mech-anosensing of Shear Stress. Circ Res, 2002; 91: 769-775
68. Olesen S P, Clapham DE, Davies PF: Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature, 1988; 331: 168-170
69. Jacobs ER, Cheliakine C, Gebremedhin D, Birks EK, Davies P F, Harder DR: Shear activated channels in cell-attached patches of cultured bovine aortic endothelial cells. Pflugers Arch, 1995; 431: 129-131
70. Barakat AI, Leaver EV, Pappone PA, Davies PF: A flow-activated chloride-selective membrane current in vascular endothelial cells. Circ Res, 1999; 85: 820-828
71. Nakao M, Ono K, Fujisawa S, Iijima T: Mechanical stress-induced Ca2+ entry and Cl- current in cultured human aortic endothelial cells. Am J Physiol, 1999; 276: C238-C249
72. Langille BL, O'Donnell F: Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science, 1986; 231: 405-407
73. Rodbard S: Negative feedback mechanisms in the architecture and function of the connective and cardiovascular tissues. Perspect Biol Med, 1970; 13: 507-527
74. Furchgott R F, Zawadzki JV: The obligatory role of endo-thelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980; 299: 373-376
75. Rubanyi GM, Romero JC, Vanhoutte PM: Flow-induced release of endothelium-derived relaxing factor. Am J Physiol, 1986; 250: H1145-H1149
76. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA, 1987; 84: 9265-9269
77. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987; 327: 524-526
78. Palmer RM, Ashton DS, Moncada S: Vascular endothe-lial cells synthesize nitric oxide from L-arginine. Nature, 1988; 333: 664-666
79. Rees DD, Palmer RM, Hodson HF, Moncada S: A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol, 1989; 96: 418-424
80. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol, 1990; 101: 746-752
81. Busse R, Mulsch A: Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett, 1990; 265: 133-136
82. Baron AD, Quon MJ: Insulin action and endothelial function. In: Insulin Resistance: the metabolic syndrome X, ed by Reaven GM and Ami L, Humana Press, NJ, 1999
83. Waldman SA, Murad F: Cyclic GMP synthesis and function. Pharmacol Rev, 1987; 39: 163-196
84. Feelisch M, Noack EA: Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol, 1987; 139: 19-30
85. Lincoln TM, Dey N, Sellak H: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiology, 2001; 91: 1421-1430
86. Loscalzo J, Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis, 1995; 38: 87-104
87. Huang A, Sun D, Shesely EG, Levee EM, Koller A, Kaley G: Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am J Physiol Heart Circ Physiol, 2002; 282: H429-H436
88. Lamping KG, Nuno DW, Shesely EG, Maeda N, Faraci FM: Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol, 2000; 279: H1906-H1912
89. Meng W, Ayata C, Waeber C, Huang PL, Moskowitz MA: Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout mice. Am J Physiol, 1998; 274: H411-H415
90. Harrington LS, Carrier MJ, Gallagher N, Gilroy D, Garland CJ, Mitchell JA: Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol, 2007; 293: H1682-H1688
91. Mitchell JA, de Nucci G, Warner TD, Vane JR: Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol, 1992; 105: 485-489
92. Luckhoff A, Pohl U, Mulsch A, Busse R: Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br J Pharmacol, 1988; 95: 189-196
93. Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS: Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol, 2008; 93: 141-147
94. Doshi SN, Naka KK, Payne N, Jones CJ, Ashton M, Lewis MJ, Goodfellow J: Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci (Lond), 2001; 101: 629-635
95. Lieberman EH, Gerhard MD, Uehata A, Selwyn A P, Ganz P, Yeung AC, Creager MA: Flow-induced vasodila-tion of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol, 1996; 78: 1210-1214
96. Liuni A, Luca MC, Lisi M, Dragoni S, di Stolfo G, Mar-iani JA, Uxa A, Gori T, Parker JD: Observations of time-based measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. Am J Physiol Heart Circ Physiol, 2010; 299: H939-945
97. Bellien J, Iacob M, Eltchaninoff H, Bourkaib R, Thuillez C, Joannides R: AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans. Clin Sci (Lond), 2007; 112: 393-401
98. Pyke K, Green DJ, Weisbrod C, Best M, Dembo L, O'Driscoll G, Tschakovsky M: Nitric oxide is not obligatory for radial artery flow-mediated dilation following release of 5 or 10 min distal occlusion. Am J Physiol Heart Circ Physiol, 2010; 298: H119-H126
99. Fischer D, Landmesser U, Spiekermann S, Hilfiker-Kleiner D, Hospely M, Muller M, Busse R, Fleming I, Drexler H: Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail, 2007; 9: 770-775
100. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, Deanfield JE, MacAllister RJ: Heteroge-nous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res, 2001; 88: 145-151
101. Seddon M, Melikian N, Dworakowski R, Shabeeh H, Jiang B, Byrne J, Casadei B, Chowienczyk P, Shah AM: Effects of neuronal nitric oxide synthase on human coronary artery diameter and blood flow in vivo. Circulation, 2009; 119: 2656-2662
102. Grabowski E F, Jaffe EA, Weksler BB: Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. J Lab Clin Med, 1985; 105: 36-43
103. Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR: Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prosta-glandins, 1976; 12: 685-713
104. Moncada S, Higgs EA, Vane JR: Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet, 1977; 1: 18-20
105. Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest, 2006; 116: 4-15
106. Arehart E, Gleim S, Kasza Z, Fetalvero KM, Martin KA, Hwa J: Prostacyclin, atherothrombosis, and cardiovascular disease. Curr Med Chem, 2007; 14: 2161-2169
107. Vane JR: Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prosta-cyclin. Br J Pharmacol, 1983; 79: 821-838
108. Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 1976; 263: 663-665
109. Osanai T, Fujita N, Fujiwara N, Nakano T, Takahashi K, Guan W, Okumura K: Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells. Am J Physiol Heart Circ Physiol, 2000; 278: H233-H238
110. Duffy SJ, Castle S F, Harper RW, Meredith IT: Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation, 1999; 100: 1951-1957
111. Schrage WG, Wilkins BW, Johnson C P, Eisenach JH, Limberg JK, Dietz NM, Curry TB, Joyner MJ: Roles of nitric oxide synthase and cyclooxygenase in leg vasodila-tion and oxygen consumption during prolonged low-intensity exercise in untrained humans. J Appl Physiol, 2010; 109: 768-777
112. Markwald RR, Kirby BS, Crecelius AR, Carlson RE, Voyles W F, Dinenno FA: Combined inhibition of nitric oxide and vasodilating prostaglandins abolishes forearm vasodilatation to systemic hypoxia in healthy humans. J Physiol, 2011; 589: 1979-1990
113. Nicholson W T, Vaa B, Hesse C, Eisenach JH, Joyner MJ: Aging is associated with reduced prostacyclin-medi-ated dilation in the human forearm. Hypertension, 2009; 53: 973-978
114. Matthews JS, McWilliams PJ, Key BJ, Keen M: Inhibition of prostacyclin release from cultured endothelial cells by nitrovasodilator drugs. Biochim Biophys Acta, 1995; 1269: 237-242
115. Beverelli F, Bea ML, Puybasset L, Giudicelli J F, Berdeaux A: Chronic inhibition of NO synthase enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type I isoform. Clin Pharmacol, 1997; 11: 252-259
116. Barker JE, Bakhle YS, Anderson J, Treasure T, Piper PJ: Reciprocal inhibition of nitric oxide and prostacyclin synthesis in human saphenous vein. Br J Pharmacol, 1996; 118: 643-648
117. Koller A, Huang A: Impaired nitric oxide-mediated flow-induced dilation in arterioles of spontaneously hypertensive rats. Circ Res, 1994; 74: 416-421
118. Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I, Salvetti A: Hypertension causes premature aging of endothelial function in humans. Hypertension, 1997; 29: 736-743
119. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A: Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation, 1995; 91: 1981-1987
120. Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension, 1993; 21: 929-933
121. Ignarro LJ: Biological actions and properties of endothe-lium-derived nitric oxide formed and released from artery and vein. Circ Res, 1989; 65: 1-21
122. Golding EM, Marrelli S P, You J, Bryan RM: Endothe-lium-derived hyperpolarizing factor in the brain: a new regulator of cerebral blood flow? Stroke, 2002; 33: 661-663
123. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH: K+ is an endothelium-derived hyperpolar-izing factor in rat arteries. Nature, 1998; 396: 269-272
124. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A: Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol, 2006; 48: 508-515
125. Wei CM, Hu S, Miller VM, Burnett JC: Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun, 1994; 205: 765-771
126. Faraci FM, Sobey CG, Chrissobolis S, Lund DD, Heis-tad DD, Weintraub NL: Arachidonate dilates basilar artery by lipoxygenase-dependent mechanism and activation of K(+) channels. Am J Physiol Regul Integr Comp Physiol, 2001; 281: R246-R253
127. Ellis A, Triggle CR: Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol Pharmacol, 2003; 81: 1013-1028
128. Inokuchi K, Hirooka Y, Shimokawa H, Sakai K, Kishi T, Ito K, Kimura Y, Takeshita A: Role of endothelium-derived hyperpolarizing factor in human forearm circulation. Hypertension, 2003; 42: 919-924
129. Passauer J, Bussemaker E, Lassig G, Pistrosch F, Fauler J, Gross P, Fleming I: Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin Sci (Lond), 2003; 105: 513-518
130. Bellien J, Thuillez C, Joannides R: Role of endothelium-derived hyperpolarizing factor in the regulation of radial artery basal diameter and endothelium-dependent dilatation in vivo. Clin Exp Pharmacol Physiol, 2008; 35:494-497
131. Bellien J, Iacob M, Gutierrez L, Isabelle M, Lahary A, Thuillez C, Joannides R: Crucial role of NO and endo-thelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension, 2006; 48: 1088-1094
132. Nishikawa Y, Stepp DW, Chilian WM: Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol, 2000; 279: H459-H465
133. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A: Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest, 1997; 100: 2793-2799
134. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A: The importance of the hyper-polarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol, 1996; 28: 703-711
135. Luksha L, Agewall S, Kublickiene K: Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis, 2009; 202: 330-344
136. Cohen RA, Vanhoutte PM: Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation, 1995; 92: 3337-3349
137. Clark SG, Fuchs LC: BK(Ca) channels compensate for loss of NOS-dependent coronary artery relaxation in cardiomyopathy. Am J Physiol Heart Circ Physiol, 2000; 279: H2598-H2603
138. Taddei S, Virdis A, Ghiadoni L, Versari D, Salvetti A: Endothelium, aging, and hypertension. Curr Hypertens Rep, 2006; 8: 84-89
139. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gut-terman DD: Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res, 2003; 92: e31-e40
140. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH: EDHF: Bringing the concepts together. Trends Pharmacol Sci, 2002; 23: 374-380
141. Miura H, Gutterman DD: Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2+-activated K+ channels. Circ Res, 1998; 83: 501-507
142. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, Salvetti A: Age-related reduction of NO availability and oxidative stress in humans. Hypertension, 2001; 38: 274-279
143. Taddei S, Galetta F, Virdis A, Ghiadoni L, Salvetti G, Franzoni F, Giusti C, Salvetti A: Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation, 2000; 101: 2896-2901
144. Nishikawa Y, Stepp DW, Chilian WM: Nitiric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol, 2000; H459-H465
145. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R: Nitric oxide attenuates the release of endothe-lium-derived hyperpolarizing factor. Circulation, 1996; 94: 3341-3347 146)
146. Agewall S, Hulthe J, Fagerberg B, Gottfridsson B, Wik-strand J: Post-occlusion brachial artery vasodilatation after ischaemic handgrip exercise is nitric oxide mediated. Clin Physiol Funct Imaging, 2002; 22: 18-23
147. Owens CD, Wake N, Conte MS, Gerhard-Herman M, Beckman JA: In vivo human lower extremity saphenous vein bypass grafts manifest flow mediated vasodilation. J Vasc Surg, 2009; 50: 1063-1070